Clinical trial · Interventional
Study for Treatment of Cancer in Children With Ataxia-telangiectasia
Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia
NCT00187057CI-TRIAL-00018974completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot/feasibility study designed to investigate the feasibility of treating children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as non-A-T patients with cancer would receive.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ataxia-Telangiectasia | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy, intrathecal chemotherapy, steroid therapy | Procedure | — | UNRESOLVED |
| dexamethasone, procarbazine | Drug | — | UNRESOLVED |
| doxorubicin, methotrexate, cyclophosphamide, L-asparaginase | Drug | — | UNRESOLVED |
| etoposide, cytarabine, mercaptopurine | Drug | — | UNRESOLVED |
| vinblastine, vincristine, prednisone, daunorubicin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- OTHER
- label
- 1
- description
- Acute Lymphoblastic Leukemia (ALL) Low Risk
- interventionNames
- Drug: vinblastine, vincristine, prednisone, daunorubicin
- Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
- Drug: etoposide, cytarabine, mercaptopurine
- Drug: dexamethasone, procarbazine
- Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
- type
- OTHER
- label
- 2
- description
- Acute Lymphoblastic Leukemia (ALL) - High Risk
- interventionNames
- Drug: vinblastine, vincristine, prednisone, daunorubicin
- Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
- Drug: etoposide, cytarabine, mercaptopurine
- Drug: dexamethasone, procarbazine
- Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 10 Years
Show eligibility criteria text
Inclusion Criteria: * Patient must have a diagnosis of Ataxia-Telangiectasia (A-T). * Patient must have a diagnosis of either acute lymphoblastic leukemia (ALL) or lymphoma (non-Hodgkin lymphoma or Hodgkin's disease). * Patients with other malignancies (solid tumors, rare malignancies, or relapsed hematopoietic malignancies) will be eligible for the biologic studies of this protocol; they will receive best clinical management chemotherapy. * Patients do not have to be previously untreated. If prior chemotherapy has already started (up through induction), therapy will be continued according to protocol at a clinically appropriate time point. Exclusion Criteria: * Patients who do not have a diagnosis of Ataxia Telangiectasia (A-T).
References
Publications (1)
- BACKGROUNDSandlund JT, Kastan MB, Kennedy W, Behm F, Entrekin E, Pui CH, Kalwinsky DT, Raimondi SC. A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia. Cancer Genet Cytogenet. 2006 Jul 1;168(1):69-72. doi: 10.1016/j.cancergencyto.2005.12.013. PMID 16772123